高级搜索
63例Ⅰ~Ⅲ期肾细胞癌患者术后辅助治疗疗效及预后因素分析[J]. 肿瘤防治研究, 2011, 38(09): 1062-1065. DOI: 10.3971/j.issn.1000-8578.2011.09.023
引用本文: 63例Ⅰ~Ⅲ期肾细胞癌患者术后辅助治疗疗效及预后因素分析[J]. 肿瘤防治研究, 2011, 38(09): 1062-1065. DOI: 10.3971/j.issn.1000-8578.2011.09.023
Treatment Effect and Prognostic Factors of Postoperative Therapy for 63 Patients with Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(09): 1062-1065. DOI: 10.3971/j.issn.1000-8578.2011.09.023
Citation: Treatment Effect and Prognostic Factors of Postoperative Therapy for 63 Patients with Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(09): 1062-1065. DOI: 10.3971/j.issn.1000-8578.2011.09.023

63例Ⅰ~Ⅲ期肾细胞癌患者术后辅助治疗疗效及预后因素分析

Treatment Effect and Prognostic Factors of Postoperative Therapy for 63 Patients with Renal Cell Carcinoma

  • 摘要: 目的研究肾细胞癌术后辅助治疗的疗效及影响患者远期生存的因素。方法回顾性分析63例肾细胞癌患者术后辅助治疗的效果,多因素分析影响生存期的因素。结果全组5年生存率为71.0%;病理分期Ⅰ、Ⅱ和Ⅲ期患者5年生存率分别87.7%、70.3%和42.9%(χ2=11.629,P=0.003),T1、T2和T3期患者的5年生存率分别为88.7%、63.9%和37.0%(χ2=11.850,P=0.003),N0和N1患者的5年生存率分别为78.0%和35.6%(χ2=8.599,P=0.003),有、无静脉瘤栓的患者5年生存率分别为31.3%和76.0%(χ2=8.108,P=0.004)。全组局部复发率和远处转移率分别为15.9%(10/63)和23.8%(15/63)。多因素分析表明T分期(P=0.021)、N分期(P=0.040)、手术切除(P=0.032)、术后生物化疗(P=0.022)、术后放疗(P=0.042)是影响患者总生存期的独立预后因素。结论TNM分期是患者能否远期生存的决定性因素,术后辅助生物化疗和辅助放疗可提高总生存率,但需要进一步大样本随机对照研究。

     

    Abstract: ObjectiveTo study the long-term results and prognostic factors of postoperative treatment for patients with renal cell carcinoma who underwent the surgical resection. Methods Sixty-three patients with renal cell carcinoma who received postoperative treatment were enrolled into our retrospective study.We analyzed the 5-year survival rate,the occurrence of the local relapse and distant metastasis.The prognostic factors were determined by Cox proportional risk model.ReusltsThe 5-year overall suruvival rate of the whole group was 71.0%.The 5-year overall rate for the patients in stageⅠ,Ⅱ and Ⅲ was 87.7%,70.3% and 42.9%,respectively(χ2= 11.629,P=0.003).That in T1, T2 and T3 was 88.7%,63.9%,37.0%,respectively(χ2=11.850,P=0.003).That in N0 and N1 was 78.0% and 35.6%(χ2=8.599,P=0.003),respectively.That for the patients with or without cancerous embolism was 31.3% and 76.0%,respectively(χ2=8.108,P=0.004).The rates of local recurence and distant metastasis were 15.9%(10/63)and 23.8%(15/63),respectively. With Cox analysis,T staging (P=0.021),N staging(P=0.040),the surgical resection (P=0.032),postoperative biochemotherapy(P=0.022) and postoperative radiation(P=0.042)were the independent prognostic factors affecting the patients' survial. ConclusionFor patients with renal cell carcinoma,TNM staging is the most important factor predicting the patients' survival time.The value of postoperative biochemotherapy and(or) radiotherapy needs to be further investigated.

     

/

返回文章
返回